Quanterix Corporation (NASDAQ: QTRX) is a Healthcare company (Medical - Devices) with a market capitalization of $136M. The Maz Rating grades it against the other companies in its sector.
Quanterix Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $2.86, Quanterix Corporation trades at 0.9x sales and 0.6x book value. Over the last twelve months it generated about $148M of revenue and a net loss of $112M. It runs a gross margin of 41.6%, an operating margin of -79.2% and a net margin of -75.0%. It shows return on equity of -43.0%, return on invested capital of -45.7% and a free cash flow yield of -41.3%. On the balance sheet: a debt-to-equity ratio of 0.14 and a current ratio of 3.09. Over the past 52 weeks the share price ranged from $2.15 to $8.77, with a beta of 1.04.
Quanterix Corporation does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 5 Buy and 5 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Quanterix Corporation (QTRX) passes 1 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI, and fails AAOIFI, S&P Global, Dow Jones and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 55.2% / 30% · Interest income / Revenue 1.90% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 55.2% / 33% · Receivables / Mkt Cap (36m) 19.4% / 49% · Interest income / Revenue 1.90% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 55.2% / 33.33% · Receivables / Mkt Cap (24m) 19.4% / 33.33% · Interest income / Revenue 1.90% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 27.6% / 33.33% · Receivables / Avg Assets (4Q) 7.56% / 33.33% · Interest income / Revenue 1.90% / 5% | Pass |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 25.7% / 33.33% · (Cash+Recv) / Total Assets 34.8% / 33.33% · Interest income / Revenue 1.90% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Quanterix Corporation (QTRX) passes 1 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI, and fails AAOIFI, S&P Global, Dow Jones and FTSE.
No. Quanterix Corporation is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
About 1.90% of each dividend: Quanterix Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.